Nationwide alert in China for the faulty rabies vaccine

The second largest drug manufacturing company “ Changchun Changsheng Life Sciences” were found guilty for violated national standards including usage of expired fluids and falsified production dates to produce rabies vaccine. Rabies Vaccines manufactured in China was widely exported to countries including India too.

This recent scandal of faulty Rabies Vaccines creating panic and especially in China. After taking a quick action on this, country has started a nationwide campaign to provide health consultation and free inoculation of rabies vaccines.

In India, the Drug Controller General of India also ordered immediately to withdraw rabies vaccines from the market and also banned their imports from Changchun Changsheng Life Sciences.

Healthcare centers, institutions and disease control centers have started providing consultation services for those who received or used rabies vaccines made by the company. 36,482 hospitals and health centers are designated by the China government to provide consultation. No life loss has been reported yet from the patients who injected with the faulty Rabies vaccines.

According to the report, Changchun Changsheng making use of expired fluids and false production dates is in continuity since April 2014 and had violated rules on production management and national drug standards for the vaccines.

China National Health Commission and the State Drug Administration are actively working on the issue and created an inoculation plan for patients who have injected rabies vaccines from the Changchun Changsheng company. And the patients who are getting treated and those whose required course are not yet completed can switch to vaccines from other companies at no charge.

China government also start giving free re-inoculated who have completed their courses less than a year ago and vaccination institutions will provide tracking, observation, and advisory services.

Related Posts

Eli Lilly launches cancer drug Tanstrive in India

New Delhi: Eli Lilly and Company India on Thursday announced the launch of its cancer treatment drug Tanstrive in India. The launch follows marketing authorisation from the Central Drugs Standard Control Organisation…

Centre eases BIS quality compliance with new risk-based framework for manufacturers

The Centre has introduced a risk-based compliance mechanism to ease industry compliance with Quality Control Orders (QCOs), allowing eligible manufacturers to follow a simplified certification route while maintaining product quality…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Eli Lilly launches cancer drug Tanstrive in India

Eli Lilly launches cancer drug Tanstrive in India

Sir Ganga Ram Hospital excels in Medical Research among Private Hospitals

Sir Ganga Ram Hospital excels in Medical Research among Private Hospitals

Centre eases BIS quality compliance with new risk-based framework for manufacturers

Centre eases BIS quality compliance with new risk-based framework for manufacturers

SS Innovations International aces Race beating Global Giants in Surgical Robotics

SS Innovations International aces Race beating Global Giants in Surgical Robotics

‘SHE’ comes all the Way from Calcutta to Delhi to Care for Women’s Fertility

‘SHE’ comes all the Way from Calcutta to Delhi to Care for Women’s Fertility

India curbs supply of IVF consumables to unregistered clinics

India curbs supply of IVF consumables to unregistered clinics